Halozyme Therapeutics, Inc. or CRISPR Therapeutics AG: Who Manages SG&A Costs Better?

Managing SG&A Costs: A Tale of Two Biotech Innovators

In the competitive world of biotechnology, managing Selling, General, and Administrative (SG&A) expenses is crucial for maintaining financial health. Halozyme Therapeutics, Inc. and CRISPR Therapeutics AG, two pioneers in the field, have shown contrasting approaches over the past decade. From 2014 to 2023, Halozyme's SG&A expenses surged by approximately 315%, peaking in 2023. In contrast, CRISPR Therapeutics saw a more moderate increase of around 1,390% over the same period, with a notable peak in 2021. Interestingly, while Halozyme's expenses were consistently higher, CRISPR's expenses caught up significantly by 2021, reaching nearly 100% of Halozyme's 2014 levels. This data highlights the dynamic strategies these companies employ to balance innovation with operational efficiency. As the biotech landscape evolves, monitoring these trends offers valuable insights into the financial strategies of industry leaders.